Primary metastatic prostate cancer between prognosis or adequate/proper medical therapy
Abstract Purpose To define the efficacy of standard androgen deprivation therapy (ADT) in the treatment of metastatic prostate cancer (PCa). Materials and methods Fifty patients with mean age of 70.48 ± 9.95 years old (range 52–87) who had metastatic PCa and received ADT between 2014 and 2019 were r...
Main Authors: | Mahmoud Mustafa, Honood Abu Rass, Mothafr Yahya, Khaleel Hamdan, Yazan Eiss |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-01-01
|
Series: | World Journal of Surgical Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12957-020-02111-3 |
Similar Items
-
Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations
by: Castellan P, et al.
Published: (2018-12-01) -
Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer
by: Carlo Cattrini, et al.
Published: (2019-09-01) -
Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice
by: Atsushi Mizokami, et al.
Published: (2017-01-01) -
Efficacy of Treatment for Metastatic Hormone-Sensitive Prostate Cancer: An Umbrella Review of Systematic Reviews and Meta-Analyses
by: Pokket Sirisreetreerux, et al.
Published: (2023-12-01) -
Recent Scientific Developments in Metastatic Prostate Cancer
by: Isabel Heidegger
Published: (2020-11-01)